359 related articles for article (PubMed ID: 20183436)
1. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
Masaki N; Koyama T; Yoshimura I; Hamada C
J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
[TBL] [Abstract][Full Text] [Related]
2. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
3. Targeting population entering phase III trials: a new stratified adaptive phase II design.
Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
6. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
Polley MY; Cheung YK
Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
[TBL] [Abstract][Full Text] [Related]
7. An adjustment for patient heterogeneity in the design of two-stage phase II trials.
Sposto R; Gaynon PS
Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973
[TBL] [Abstract][Full Text] [Related]
8. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
9. Balanced two-stage designs for phase II clinical trials.
Ye F; Shyr Y
Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
[TBL] [Abstract][Full Text] [Related]
10. Adaptive two-stage designs in phase II clinical trials.
Banerjee A; Tsiatis AA
Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
[TBL] [Abstract][Full Text] [Related]
11. An alternative phase II/III design for continuous endpoints.
Huang WS; Liu JP; Hsiao CF
Pharm Stat; 2011; 10(2):105-14. PubMed ID: 20186724
[TBL] [Abstract][Full Text] [Related]
12. Multiplicity and flexibility in clinical trials.
Brannath W; Koenig F; Bauer P
Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
[TBL] [Abstract][Full Text] [Related]
13. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
14. Optimal two-stage designs for clinical trials based on safety and efficacy.
Thall PF; Cheng SC
Stat Med; 2001 Apr; 20(7):1023-32. PubMed ID: 11276033
[TBL] [Abstract][Full Text] [Related]
15. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.
Stallard N
Stat Med; 2010 Apr; 29(9):959-71. PubMed ID: 20191605
[TBL] [Abstract][Full Text] [Related]
16. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
Zhang Y; Mietlowski W; Chen B; Wang Y
J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
[TBL] [Abstract][Full Text] [Related]
17. Adaptive designs for single-arm phase II trials in oncology.
Englert S; Kieser M
Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
[TBL] [Abstract][Full Text] [Related]
18. A seamless phase II/III design with sample-size re-estimation.
Bischoff W; Miller F
J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
[TBL] [Abstract][Full Text] [Related]
19. Curtailed two-stage designs with two dependent binary endpoints.
Chen CM; Chi Y
Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
[TBL] [Abstract][Full Text] [Related]
20. Two-stage designs for phase II cancer trials with ordinal responses.
Stallard N; Cockey L
Contemp Clin Trials; 2008 Nov; 29(6):896-904. PubMed ID: 18703164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]